Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Immunosuppressive Agents"" wg kryterium: Temat


Tytuł :
Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients.
Autorzy :
Job KM; Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Roberts JK; Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Enioutina EY; Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
IIIamola SM; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Kumar SS; Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Rashid J; Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Ward RM; Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.; Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, UT, USA.
Fukuda T; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Sherbotie J; Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, UT, USA.
Sherwin CM; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.; Department of Pediatrics, Boonshoft School of Medicine, Dayton Children's Hospital, Wright State University, Dayton, OH, USA.; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
Pokaż więcej
Źródło :
Expert opinion on drug metabolism & toxicology [Expert Opin Drug Metab Toxicol] 2021 Jul; Vol. 17 (7), pp. 747-765. Date of Electronic Publication: 2021 Jun 29.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Graft Survival/*drug effects
Immunosuppressive Agents/*administration & dosage
Kidney Transplantation/*methods
Age Factors ; Child ; Drug Interactions ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/pharmacokinetics ; Polymorphism, Genetic
Czasopismo naukowe
Tytuł :
Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.
Autorzy :
Khan N; Division of Gastroenterology, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address: .
Mahmud N; Division of Gastroenterology, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania; Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Pokaż więcej
Źródło :
Gastroenterology [Gastroenterology] 2021 Sep; Vol. 161 (3), pp. 827-836. Date of Electronic Publication: 2021 May 25.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19*/complications
COVID-19*/immunology
COVID-19*/therapy
COVID-19 Vaccines*/adverse effects
Immunosuppressive Agents*/adverse effects
Immunosuppressive Agents*/immunology
Inflammatory Bowel Diseases*/complications
Inflammatory Bowel Diseases*/drug therapy
Inflammatory Bowel Diseases*/immunology
SARS-CoV-2*/drug effects
SARS-CoV-2*/immunology
Aged ; Female ; Humans ; Male ; Retrospective Studies ; Treatment Outcome ; Vaccination ; Veterans
Czasopismo naukowe
Tytuł :
Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
Autorzy :
Gong L; Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China.; Department of Nephrology, The Wujin Clinical College of Xuzhou Medical University Changzhou, Jiangsu, China.
Xu M; Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China.; Department of Nephrology, The Wujin Clinical College of Xuzhou Medical University Changzhou, Jiangsu, China.
Xu W; Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China.; Department of Nephrology, The Wujin Clinical College of Xuzhou Medical University Changzhou, Jiangsu, China.
Tang W; Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China.; Department of Nephrology, The Wujin Clinical College of Xuzhou Medical University Changzhou, Jiangsu, China.
Lu J; Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China.; Department of Nephrology, The Wujin Clinical College of Xuzhou Medical University Changzhou, Jiangsu, China.
Jiang W; Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China.; Department of Nephrology, The Wujin Clinical College of Xuzhou Medical University Changzhou, Jiangsu, China.
Xie F; Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China.; Department of Nephrology, The Wujin Clinical College of Xuzhou Medical University Changzhou, Jiangsu, China.
Ding L; Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China.; Department of Nephrology, The Wujin Clinical College of Xuzhou Medical University Changzhou, Jiangsu, China.
Qian X; Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China.; Department of Nephrology, The Wujin Clinical College of Xuzhou Medical University Changzhou, Jiangsu, China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Jul 16; Vol. 100 (28), pp. e26628.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Adrenal Cortex Hormones/*therapeutic use
Cyclophosphamide/*therapeutic use
Glomerulonephritis, Membranous/*drug therapy
Immunosuppressive Agents/*therapeutic use
Tacrolimus/*therapeutic use
Adrenal Cortex Hormones/administration & dosage ; Adrenal Cortex Hormones/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Drug Therapy, Combination ; Humans ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Remission Induction ; Tacrolimus/adverse effects
Czasopismo naukowe
Tytuł :
Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant Recipients.
Autorzy :
Fontova P; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.; Nephrology Laboratory, Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.
Colom H; Biopharmaceutics and Pharmacokinetics Unit, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Barcelona, Barcelona, Spain.
Rigo-Bonnin R; Biochemistry Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.
Bestard O; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.; Nephrology Laboratory, Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.
Vidal-Alabró A; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.; Nephrology Laboratory, Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.
van Merendonk LN; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.; Nephrology Laboratory, Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.
Cerezo G; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.; Nephrology Laboratory, Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.
Polo C; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.
Montero N; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.
Melilli E; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.
Manonelles A; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.
Meneghini M; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.
Coloma A; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.
Cruzado JM; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.; Nephrology Laboratory, Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.
Torras J; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.; Nephrology Laboratory, Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.
Grinyó JM; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.; Nephrology Laboratory, Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.
Lloberas N; Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain.; Nephrology Laboratory, Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Jul; Vol. 110 (1), pp. 238-247. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Kidney Transplantation*
Models, Biological*
Calcineurin Inhibitors/*administration & dosage
Immunosuppressive Agents/*administration & dosage
Tacrolimus/*administration & dosage
Aged ; Area Under Curve ; Calcineurin/drug effects ; Calcineurin/metabolism ; Calcineurin Inhibitors/pharmacokinetics ; Calcineurin Inhibitors/pharmacology ; Chromatography, High Pressure Liquid ; Delayed-Action Preparations ; Female ; Humans ; Immunosuppressive Agents/pharmacokinetics ; Immunosuppressive Agents/pharmacology ; Male ; Middle Aged ; Prospective Studies ; Tacrolimus/pharmacokinetics ; Tacrolimus/pharmacology ; Tandem Mass Spectrometry
Czasopismo naukowe
Tytuł :
Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Autorzy :
Wiese MD; University of South Australia, Adelaide, South Australia, Australia.
Hopkins AM; Flinders University of South Australia, Bedford Park, South Australia, Australia.
King C; University of South Australia, Adelaide, South Australia, Australia.
Wechalekar MD; Flinders University of South Australia and Flinders Medical Centre, Bedford Park, South Australia, Australia.
Lee A; Royal Adelaide Hospital and The University of Adelaide, Adelaide Medical School, Adelaide, South Australia, Australia.
Spargo L; Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Metcalf R; Royal Adelaide Hospital, Adelaide, South Australia, Australia.
McWilliams L; Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Hill C; Royal Adelaide Hospital and The University of Adelaide, Adelaide, and The Queen Elizabeth Hospital, Woodville, South Australia, Australia.
Cleland LG; Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Proudman SM; Royal Adelaide Hospital and The University of Adelaide, Adelaide Medical School, Adelaide, South Australia, Australia.
Pokaż więcej
Źródło :
Arthritis care & research [Arthritis Care Res (Hoboken)] 2021 Jul; Vol. 73 (7), pp. 983-989.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Pharmacogenomic Variants*
Polymorphism, Single Nucleotide*
Arthritis, Rheumatoid/*drug therapy
Crotonates/*pharmacokinetics
Enzyme Inhibitors/*pharmacokinetics
Hydroxybutyrates/*pharmacokinetics
Immunosuppressive Agents/*pharmacokinetics
Leflunomide/*pharmacokinetics
Nitriles/*pharmacokinetics
Oxidoreductases Acting on CH-CH Group Donors/*antagonists & inhibitors
Oxidoreductases Acting on CH-CH Group Donors/*genetics
Toluidines/*pharmacokinetics
Adult ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/genetics ; Crotonates/blood ; Drug Monitoring ; Enzyme Inhibitors/administration & dosage ; Enzyme Inhibitors/blood ; Female ; Haplotypes ; Humans ; Hydroxybutyrates/blood ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/blood ; Leflunomide/administration & dosage ; Leflunomide/blood ; Male ; Middle Aged ; Nitriles/blood ; Oxidoreductases Acting on CH-CH Group Donors/metabolism ; Pharmacogenetics ; Precision Medicine ; Recovery of Function ; Remission Induction ; Toluidines/blood ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A systematic overview of the spermatotoxic and genotoxic effects of methotrexate, ganciclovir and mycophenolate mofetil.
Autorzy :
Jensen NB; Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Justesen SD; Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Larsen A; Department of Biomedicine, Aarhus University, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Ernst E; Department of Biomedicine, Aarhus University, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Laboratory for Reproduction, Institute of Anatomy, Aarhus University, Aarhus, Denmark.
Pedersen LH; Department of Biomedicine, Aarhus University, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Obstetrics and Gynecology, Aarhus University Hospital, Aarhus, Denmark.
Pokaż więcej
Źródło :
Acta obstetricia et gynecologica Scandinavica [Acta Obstet Gynecol Scand] 2021 Sep; Vol. 100 (9), pp. 1557-1580. Date of Electronic Publication: 2021 Apr 15.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Ganciclovir/*toxicity
Immunosuppressive Agents/*toxicity
Methotrexate/*toxicity
Mycophenolic Acid/*toxicity
DNA Damage/drug effects ; Ganciclovir/pharmacology ; Humans ; Immunosuppressive Agents/pharmacology ; Male ; Methotrexate/pharmacology ; Mycophenolic Acid/pharmacology ; Spermatozoa/drug effects
Czasopismo naukowe
Tytuł :
Efficacy of tacrolimus as maintenance therapy after cyclophosphamide for treating antineutrophil cytoplasmic antibody-associated vasculitis.
Autorzy :
Pyo JY; Division of Rheumatology, Department of Internal Medicine.
Lee LE; Division of Rheumatology, Department of Internal Medicine.
Ahn SS; Division of Rheumatology, Department of Internal Medicine.
Song JJ; Division of Rheumatology, Department of Internal Medicine.; Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea.
Park YB; Division of Rheumatology, Department of Internal Medicine.; Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea.
Lee SW; Division of Rheumatology, Department of Internal Medicine.; Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Aug 27; Vol. 100 (34), pp. e26956.
Typ publikacji :
Journal Article
MeSH Terms :
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug therapy
Azathioprine/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Tacrolimus/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/pathology ; Azathioprine/adverse effects ; Cyclophosphamide/therapeutic use ; Disease Progression ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Incidence ; Kidney Failure, Chronic/pathology ; Male ; Middle Aged ; Recurrence ; Retrospective Studies ; Survival Rate ; Tacrolimus/adverse effects
Czasopismo naukowe
Tytuł :
Regression of giant condilloma after removal of immunosuppressive treatment.
Autorzy :
Hernandis Villalba JV; Servicio de Cirugía General y del Aparato Digestivo. Hospital General Universitario de Elda, Alicante, España. Electronic address: .
Fabregues Olea A; Servicio de Cirugía General y del Aparato Digestivo. Hospital General Universitario de Elda, Alicante, España.
Gil Torregrosa MJ; Servicio de Cirugía General y del Aparato Digestivo. Hospital General Universitario de Elda, Alicante, España.
Pokaż więcej
Transliterated Title :
Regresión de condiloma gigante tras retirada de tratamiento inmunodepresor.
Źródło :
Medicina clinica [Med Clin (Barc)] 2021 Aug 27; Vol. 157 (4), pp. 209-210. Date of Electronic Publication: 2020 Sep 03.
Typ publikacji :
Letter
MeSH Terms :
Giant Cells*
Immunosuppressive Agents*/therapeutic use
Humans
Opinia redakcyjna
Tytuł :
Multiple Sclerosis: Focus on Extracellular and Artificial Vesicles, Nanoparticles as Potential Therapeutic Approaches.
Autorzy :
Nuzzo D; Istituto per la Ricerca e l'Innovazione Biomedica, CNR, via U. La Malfa 153, 90146 Palermo, Italy.; Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Università di Palermo, Viale delle Scienze, 90128 Palermo, Italy.
Picone P; Istituto per la Ricerca e l'Innovazione Biomedica, CNR, via U. La Malfa 153, 90146 Palermo, Italy.; Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Università di Palermo, Viale delle Scienze, 90128 Palermo, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Aug 18; Vol. 22 (16). Date of Electronic Publication: 2021 Aug 18.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Delivery Systems*
Blood-Brain Barrier/*metabolism
Extracellular Vesicles/*chemistry
Immunosuppressive Agents/*pharmacology
Liposomes/*administration & dosage
Multiple Sclerosis/*drug therapy
Nanoparticles/*administration & dosage
Animals ; Blood-Brain Barrier/drug effects ; Humans ; Immunosuppressive Agents/administration & dosage ; Liposomes/chemistry ; Multiple Sclerosis/metabolism ; Multiple Sclerosis/pathology ; Nanoparticles/chemistry
Czasopismo naukowe
Tytuł :
SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.
Autorzy :
Wellens J; Translational Gastro-Intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK.; Translational Research for Gastrointestinal Diseases, University Hospitals Leuven, Leuven, Belgium.
Colombel JF; Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Satsangi JJ; Translational Gastro-Intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK.
Wong SY; Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2021 Aug 02; Vol. 15 (8), pp. 1376-1386.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Vaccination*/methods
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Immunosuppressive Agents/*immunology
Inflammatory Bowel Diseases/*drug therapy
Humans ; Immunity, Cellular ; Immunity, Humoral ; Immunosuppressive Agents/therapeutic use ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
Autorzy :
Schramm R; Klinik für Thorax- und Kardiovaskularchirurgie, Herz und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany.
Costard-Jäckle A; Klinik für Thorax- und Kardiovaskularchirurgie, Herz und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany. .
Rivinius R; Klinik für Kardiologie, Angiologie Und Pneumologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 672, 69120, Heidelberg, Germany.
Fischer B; Institut für Transfusions- Und Labormedizin, Herz Und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany.
Müller B; Institut für Transfusions- Und Labormedizin, Herz Und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany.
Boeken U; Klinik für Herzchirurgie, Universitätsklinikum Düsseldorf, Heinrich Heine Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.
Haneya A; Klinik für Herznahe- und Gefäßchirurgie, Universitätsklinikum Schleswig-Holstein, Arnold-Heller-Str. 3, 24105, Kiel, Germany.
Provaznik Z; Klinik für Herz-, Thorax- Und Herznahe Gefäßchirurgie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Knabbe C; Institut für Transfusions- Und Labormedizin, Herz Und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany.
Gummert J; Klinik für Thorax- und Kardiovaskularchirurgie, Herz und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany.
Pokaż więcej
Źródło :
Clinical research in cardiology : official journal of the German Cardiac Society [Clin Res Cardiol] 2021 Aug; Vol. 110 (8), pp. 1142-1149. Date of Electronic Publication: 2021 Jul 09.
Typ publikacji :
Journal Article
MeSH Terms :
Immunogenicity, Vaccine*
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
Heart Transplantation/*adverse effects
Immunity, Cellular/*drug effects
Immunity, Humoral/*drug effects
Immunosuppressive Agents/*adverse effects
Lung Transplantation/*adverse effects
Adolescent ; Adult ; Aged ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; COVID-19/immunology ; COVID-19 Vaccines/adverse effects ; Case-Control Studies ; Female ; Heart-Lung Transplantation/adverse effects ; Humans ; Immunization Schedule ; Immunocompromised Host ; Immunosuppressive Agents/administration & dosage ; Male ; Middle Aged ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; Transplant Recipients ; Vaccination ; Young Adult
Czasopismo naukowe
Tytuł :
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa.
Autorzy :
Chung SA; University of California, San Francisco.
Gorelik M; Columbia University, New York, New York.
Langford CA; Cleveland Clinic Foundation, Cleveland, Ohio.
Maz M; University of Kansas Medical Center, Kansas City.
Abril A; Mayo Clinic, Jacksonville, Florida.
Guyatt G; McMaster University, Hamilton, Ontario, Canada.
Archer AM; Northwestern University, Chicago, Illinois.
Conn DL; Emory University, Atlanta, Georgia.
Full KA; Springfield, Illinois.
Grayson PC; National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Ibarra MF; Children's Mercy Hospital, Kansas City, Missouri.
Imundo LF; Columbia University, New York, New York.
Kim S; University of California, San Francisco.
Merkel PA; University of Pennsylvania, Philadelphia.
Rhee RL; University of Pennsylvania, Philadelphia.
Seo P; Johns Hopkins University, Baltimore, Maryland.
Stone JH; Massachusetts General Hospital, Boston.
Sule S; Children's National Hospital, Washington, DC.
Sundel RP; Boston Children's Hospital, Boston, Massachusetts.
Vitobaldi OI; Chicago, Illinois.
Warner A; Saint Luke's Health System, Kansas City, Missouri.
Byram K; Vanderbilt University, Nashville, Tennessee.
Dua AB; Northwestern University, Chicago, Illinois.
Husainat N; SSM Health-St. Mary's Hospital, St. Louis, Missouri.
James KE; University of Utah, Salt Lake City.
Kalot M; State University of New York at Buffalo.
Lin YC; University of South Florida, Tampa.
Springer JM; University of Kansas Medical Center, Kansas City.
Turgunbaev M; American College of Rheumatology, Atlanta, Georgia.
Villa-Forte A; Cleveland Clinic Foundation, Cleveland, Ohio.
Turner AS; American College of Rheumatology, Atlanta, Georgia.
Mustafa RA; University of Kansas Medical Center, Kansas City, and McMaster University, Hamilton, Ontario, Canada.
Pokaż więcej
Źródło :
Arthritis care & research [Arthritis Care Res (Hoboken)] 2021 Aug; Vol. 73 (8), pp. 1061-1070. Date of Electronic Publication: 2021 Jul 08.
Typ publikacji :
Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Cyclophosphamide/*therapeutic use
Glucocorticoids/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Polyarteritis Nodosa/*drug therapy
Rheumatology/*standards
Clinical Decision-Making ; Consensus ; Cyclophosphamide/adverse effects ; Decision Support Techniques ; Drug Therapy, Combination ; Evidence-Based Medicine/standards ; Glucocorticoids/adverse effects ; Humans ; Immunosuppressive Agents/adverse effects ; Polyarteritis Nodosa/diagnosis ; Polyarteritis Nodosa/immunology ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Autorzy :
Chung SA; University of California, San Francisco.
Langford CA; Cleveland Clinic, Cleveland, Ohio.
Maz M; University of Kansas Medical Center, Kansas City.
Abril A; Mayo Clinic, Jacksonville, Florida.
Gorelik M; Columbia University, New York, New York.
Guyatt G; McMaster University, Hamilton, Ontario, Canada.
Archer AM; Northwestern University, Chicago, Illinois.
Conn DL; Emory University, Atlanta, Georgia.
Full KA; Springfield, Illinois.
Grayson PC; National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Ibarra MF; Children's Mercy Hospital, Kansas City, Missouri.
Imundo LF; Columbia University, New York, New York.
Kim S; University of California, San Francisco.
Merkel PA; University of Pennsylvania, Philadelphia.
Rhee RL; University of Pennsylvania, Philadelphia.
Seo P; Johns Hopkins University, Baltimore, Maryland.
Stone JH; Massachusetts General Hospital, Boston.
Sule S; Children's National Hospital, Washington, DC.
Sundel RP; Boston Children's Hospital, Boston, Massachusetts.
Vitobaldi OI; Chicago, Illinois.
Warner A; Saint Luke's Health System, Kansas City, Missouri.
Byram K; Vanderbilt University, Nashville, Tennessee.
Dua AB; Northwestern University, Chicago, Illinois.
Husainat N; SSM Health-St. Mary's Hospital, St. Louis, Missouri.
James KE; University of Utah, Salt Lake City.
Kalot MA; State University of New York at Buffalo.
Lin YC; University of South Florida, Tampa.
Springer JM; University of Kansas Medical Center, Kansas City.
Turgunbaev M; American College of Rheumatology, Atlanta, Georgia.
Villa-Forte A; Cleveland Clinic, Cleveland, Ohio.
Turner AS; American College of Rheumatology, Atlanta, Georgia.
Mustafa RA; University of Kansas Medical Center, Kansas City, and McMaster University, Hamilton, Ontario, Canada.
Pokaż więcej
Źródło :
Arthritis care & research [Arthritis Care Res (Hoboken)] 2021 Aug; Vol. 73 (8), pp. 1088-1105. Date of Electronic Publication: 2021 Jul 08.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug therapy
Antibodies, Antineutrophil Cytoplasmic/*blood
Immunosuppressive Agents/*therapeutic use
Rheumatology/*standards
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/immunology ; Biomarkers/blood ; Clinical Decision-Making ; Consensus ; Decision Support Techniques ; Evidence-Based Medicine/standards ; Humans ; Immunosuppressive Agents/adverse effects ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Is Busulfan Clearance Different in Patients With Sickle Cell Disease? Let's Clear Up That Case With Some Controls.
Autorzy :
Remy A; Department of Pediatric Hematology, Univ. Lille, CHU Lille, Lille, France.; Unité de pharmacologie clinique.
Théorêt Y; Unité de pharmacologie clinique.; Departments of Pharmacology and Physiology.; Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Université de Montréal.
Ansari M; CANSEARCH Research Laboratory, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva.; Department of Women-Children-Adolescents, Division of General Pediatrics, Pediatric Onco-Hematology Unit, Geneva University Hospital, Geneva, Switzerland.
Bittencourt H; Pediatrics.; Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Université de Montréal.
Ducruet T; Applied Clinical Research Unit, CHU Sainte-Justine, Montreal, QC, Canada.
Nava T; CANSEARCH Research Laboratory, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva.; Department of Women-Children-Adolescents, Division of General Pediatrics, Pediatric Onco-Hematology Unit, Geneva University Hospital, Geneva, Switzerland.
Pastore Y; Pediatrics.; Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Université de Montréal.
Rezgui MA; Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Université de Montréal.
Krajinovic M; Departments of Pharmacology and Physiology.; Pediatrics.; Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Université de Montréal.
Kleiber N; Departments of Pharmacology and Physiology.; Pediatrics.; Research Center, CHU Sainte-Justine.
Pokaż więcej
Źródło :
Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2021 Aug 01; Vol. 43 (6), pp. e867-e872.
Typ publikacji :
Journal Article
MeSH Terms :
Anemia, Sickle Cell/*metabolism
Busulfan/*pharmacokinetics
Immunosuppressive Agents/*pharmacokinetics
Adolescent ; Adult ; Anemia, Sickle Cell/therapy ; Busulfan/metabolism ; Case-Control Studies ; Child ; Child, Preschool ; Cross-Sectional Studies ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunosuppressive Agents/metabolism ; Male ; Metabolic Networks and Pathways ; Retrospective Studies ; Transplantation Conditioning ; Young Adult
Czasopismo naukowe
Tytuł :
Improvement of renal and non-renal SLE outcome measures on sirolimus therapy - A 21-year follow-up study of 73 patients.
Autorzy :
Piranavan P; Division of Rheumatology, Department of Medicine, College of Medicine, State University of New York, Syracuse, NY 13210, USA.
Perl A; Division of Rheumatology, Department of Medicine, College of Medicine, State University of New York, Syracuse, NY 13210, USA; Department of Microbiology and Immunology, College of Medicine, State University of New York, Syracuse, NY 13210, USA; Department of Biochemistry and Molecular Biology, College of Medicine, State University of New York, Syracuse, NY 13210, USA. Electronic address: .
Pokaż więcej
Źródło :
Clinical immunology (Orlando, Fla.) [Clin Immunol] 2021 Aug; Vol. 229, pp. 108781. Date of Electronic Publication: 2021 Jun 16.
Typ publikacji :
Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunosuppressive Agents/*therapeutic use
Lupus Erythematosus, Systemic/*drug therapy
Lupus Nephritis/*drug therapy
Sirolimus/*therapeutic use
Adult ; Aged ; Antibodies, Antinuclear/blood ; Cohort Studies ; Female ; Follow-Up Studies ; Humans ; Immunosuppressive Agents/adverse effects ; Lupus Erythematosus, Systemic/immunology ; Lupus Erythematosus, Systemic/physiopathology ; Lupus Nephritis/immunology ; Lupus Nephritis/physiopathology ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Sirolimus/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers.
Autorzy :
Damiani G; Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Allocco F; Studio Legale Avv. Allocco, Gardone Val Trompia, Brescia, Italy.; Centro Studi GISED, Bergamo, Italy.
Malagoli P; Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy.
Pokaż więcej
Corporate Authors :
Young Dermatologists Italian Network; Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy.
Źródło :
Clinical and experimental dermatology [Clin Exp Dermatol] 2021 Aug; Vol. 46 (6), pp. 1106-1108. Date of Electronic Publication: 2021 Apr 04.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Health Personnel*
COVID-19 Vaccines/*administration & dosage
Immunosuppressive Agents/*therapeutic use
Psoriasis/*drug therapy
Adult ; Aged ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19 Vaccines/adverse effects ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Italy ; Male ; Middle Aged ; SARS-CoV-2
Raport
Tytuł :
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
Autorzy :
Maz M; University of Kansas Medical Center, Kansas City.
Chung SA; University of California, San Francisco.
Abril A; Mayo Clinic, Jacksonville, Florida.
Langford CA; Cleveland Clinic Foundation, Cleveland, Ohio.
Gorelik M; Columbia University, New York, New York.
Guyatt G; McMaster University, Hamilton, Ontario, Canada.
Archer AM; Northwestern University, Chicago, Illinois.
Conn DL; Emory University, Atlanta, Georgia.
Full KA; Springfield, Illinois.
Grayson PC; National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Ibarra MF; Children's Mercy Hospital, Kansas City, Missouri.
Imundo LF; Columbia University, New York, New York.
Kim S; University of California, San Francisco.
Merkel PA; University of Pennsylvania, Philadelphia.
Rhee RL; University of Pennsylvania, Philadelphia.
Seo P; Johns Hopkins University, Baltimore, Maryland.
Stone JH; Massachusetts General Hospital, Boston.
Sule S; Children's National Hospital, Washington, DC.
Sundel RP; Boston Children's Hospital, Boston, Massachusetts.
Vitobaldi OI; Chicago, Illinois.
Warner A; Saint Luke's Health System, Kansas City, Missouri.
Byram K; Vanderbilt University, Nashville, Tennessee.
Dua AB; Northwestern University, Chicago, Illinois.
Husainat N; SSM Health-St. Mary's Hospital, St. Louis, Missouri.
James KE; University of Utah, Salt Lake City.
Kalot MA; State University of New York at Buffalo.
Lin YC; University of South Florida, Tampa.
Springer JM; University of Kansas Medical Center, Kansas City.
Turgunbaev M; American College of Rheumatology, Atlanta, Georgia.
Villa-Forte A; Cleveland Clinic Foundation, Cleveland, Ohio.
Turner AS; American College of Rheumatology, Atlanta, Georgia.
Mustafa RA; University of Kansas Medical Center, Kansas City, and McMaster University, Hamilton, Ontario, Canada.
Pokaż więcej
Źródło :
Arthritis care & research [Arthritis Care Res (Hoboken)] 2021 Aug; Vol. 73 (8), pp. 1071-1087. Date of Electronic Publication: 2021 Jul 08.
Typ publikacji :
Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Giant Cell Arteritis/*drug therapy
Glucocorticoids/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Rheumatology/*standards
Takayasu Arteritis/*drug therapy
Clinical Decision-Making ; Consensus ; Decision Support Techniques ; Drug Therapy, Combination ; Evidence-Based Medicine/standards ; Giant Cell Arteritis/diagnosis ; Giant Cell Arteritis/immunology ; Glucocorticoids/adverse effects ; Humans ; Immunosuppressive Agents/adverse effects ; Takayasu Arteritis/diagnosis ; Takayasu Arteritis/immunology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Case 23-2021: A 41-Year-Old Woman with Bloody Stools and Thrombocytopenia.
Autorzy :
Smibert OC; From the Peter MacCallum Cancer Centre, Austin Health, and the University of Melbourne - all in Melbourne, VIC, Australia (O.C.S.); and the Departments of Radiology (O.A.C.) and Medicine (K.G., M.B.R.), Massachusetts General Hospital, and the Departments of Radiology (O.A.C.) and Medicine (K.G., M.B.R.), Harvard Medical School - both in Boston.
Catalano OA; From the Peter MacCallum Cancer Centre, Austin Health, and the University of Melbourne - all in Melbourne, VIC, Australia (O.C.S.); and the Departments of Radiology (O.A.C.) and Medicine (K.G., M.B.R.), Massachusetts General Hospital, and the Departments of Radiology (O.A.C.) and Medicine (K.G., M.B.R.), Harvard Medical School - both in Boston.
Goodarzi K; From the Peter MacCallum Cancer Centre, Austin Health, and the University of Melbourne - all in Melbourne, VIC, Australia (O.C.S.); and the Departments of Radiology (O.A.C.) and Medicine (K.G., M.B.R.), Massachusetts General Hospital, and the Departments of Radiology (O.A.C.) and Medicine (K.G., M.B.R.), Harvard Medical School - both in Boston.
Roberts MB; From the Peter MacCallum Cancer Centre, Austin Health, and the University of Melbourne - all in Melbourne, VIC, Australia (O.C.S.); and the Departments of Radiology (O.A.C.) and Medicine (K.G., M.B.R.), Massachusetts General Hospital, and the Departments of Radiology (O.A.C.) and Medicine (K.G., M.B.R.), Harvard Medical School - both in Boston.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Jul 29; Vol. 385 (5), pp. 451-460.
Typ publikacji :
Case Reports; Clinical Conference; Journal Article
MeSH Terms :
Kidney Transplantation*
Transplant Recipients*
Abatacept/*adverse effects
Cytomegalovirus Infections/*diagnosis
Immunosuppressive Agents/*adverse effects
Purpura, Thrombocytopenic, Idiopathic/*diagnosis
Abatacept/therapeutic use ; Adult ; Cytomegalovirus Infections/complications ; Cytomegalovirus Infections/drug therapy ; Diagnosis, Differential ; Diarrhea/etiology ; Female ; Gastrointestinal Hemorrhage/etiology ; Humans ; Immunosuppressive Agents/therapeutic use ; Kidney/diagnostic imaging ; Purpura, Thrombocytopenic, Idiopathic/etiology ; Thrombocytopenia/etiology ; Tomography, X-Ray Computed
Czasopismo naukowe
Tytuł :
Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: A comparative cohort study.
Autorzy :
Speer C; Department of Nephrology, University of Heidelberg, Heidelberg, Germany.
Altenmüller-Walther C; Department of Nephrology, University of Heidelberg, Heidelberg, Germany.
Splitthoff J; Clinical Center Ludwigshafen, Department of Internal Medicine A, Ludwigshafen, Germany.
Nusshag C; Department of Nephrology, University of Heidelberg, Heidelberg, Germany.
Kälble F; Department of Nephrology, University of Heidelberg, Heidelberg, Germany.
Reichel P; Department of Nephrology, University of Heidelberg, Heidelberg, Germany.
Morath C; Department of Nephrology, University of Heidelberg, Heidelberg, Germany.
Zeier M; Department of Nephrology, University of Heidelberg, Heidelberg, Germany.
Bergner R; Clinical Center Ludwigshafen, Department of Internal Medicine A, Ludwigshafen, Germany.
Schaier M; Department of Nephrology, University of Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Jul 23; Vol. 100 (29), pp. e26733.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug therapy
Cyclophosphamide/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Cohort Studies ; Cyclophosphamide/administration & dosage ; Female ; Humans ; Immunosuppressive Agents/administration & dosage ; Male ; Middle Aged ; Recurrence ; Remission Induction ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway.
Autorzy :
Grønseth S; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, NO-7491, Trondheim, Norway. .
Rogne T; Department of Circulation and Medical Imaging, NTNU, Trondheim, Norway.
Hannula R; Department of Infectious Diseases, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
Åsvold BO; K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Trondheim, Norway.; HUNT Research Center, Department of Public Health and Nursing, NTNU, Levanger, Norway.; Department of Endocrinology, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
Afset JE; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, NO-7491, Trondheim, Norway.; Department of Medical Microbiology, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
Damås JK; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, NO-7491, Trondheim, Norway.; Department of Infectious Diseases, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.; Centre of Molecular Inflammation Research, NTNU, Trondheim, Norway.
Pokaż więcej
Źródło :
BMC infectious diseases [BMC Infect Dis] 2021 Jul 07; Vol. 21 (1), pp. 659. Date of Electronic Publication: 2021 Jul 07.
Typ publikacji :
Journal Article
MeSH Terms :
Immunocompromised Host*
Immunosuppressive Agents/*administration & dosage
Pneumocystis carinii/*isolation & purification
Pneumonia, Pneumocystis/*diagnosis
Pneumonia, Pneumocystis/*mortality
AIDS-Related Opportunistic Infections/epidemiology ; AIDS-Related Opportunistic Infections/microbiology ; Aged ; Female ; HIV Infections/epidemiology ; Hematologic Neoplasms/epidemiology ; Hospital Mortality ; Humans ; Immunosuppressive Agents/therapeutic use ; Incidence ; Male ; Middle Aged ; Norway/epidemiology ; Pneumocystis carinii/genetics ; Pneumonia, Pneumocystis/microbiology ; Polymerase Chain Reaction ; Retrospective Studies ; Risk Factors
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies